Lisa is a stock analyst with nearly 25 years of investment research experience. She earned a MBA in Finance from the University of Chicago in 1987 and began her career in investment research that same year as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of director of financial analysis.  During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy and other Fortune 1000 companies. In 2000, Lisa left to become director of investor Relations for a NYSE-listed REIT, serving in that position until the REIT was acquired. Since then, Lisa has worked as a stock analyst for independent research firms, investment newsletters and financial websites.

Analyst Articles

As an income investor, I’m always looking for companies likely to raise dividends sooner rather than later. Right now, I see good potential for dividend growth in a small corner of the REIT (real estate investment trust) universe — health care REITs. These REITS, which invest in hospitals, rehabilitation facilities and senior retirement centers, delivered a 69% increase in dividend payouts in 2010 — the largest in the industry, according to SNL Financial data. Even better, health care REITs are… Read More

As an income investor, I’m always looking for companies likely to raise dividends sooner rather than later. Right now, I see good potential for dividend growth in a small corner of the REIT (real estate investment trust) universe — health care REITs. These REITS, which invest in hospitals, rehabilitation facilities and senior retirement centers, delivered a 69% increase in dividend payouts in 2010 — the largest in the industry, according to SNL Financial data. Even better, health care REITs are expected to repeat this performance by again producing the highest REIT dividend payout in the first half of this year, according to Bloomberg data. #-ad_banner-#Health care REITs are poised to grow dividends because of more than $11 billion of industry acquisitions last year. During the real estate meltdown, these REITs were able to acquire properties at bargain prices from private sellers and grow their stream of rental income. As REIT income rises, dividends go up, since these companies are required by law to distribute the majority of their income to shareholders as dividends. An added benefit is that health care… Read More

Income investors disappointed by yields on U.S. stocks are looking outside America’s borders for bigger dividends. Emerging markets offer dividend opportunities, of course, but some investors consider them to be too risky. However, there is another market closer to home where growing dividends can be found. I’m… Read More

Have you ever wondered what it would be like to trade stocks alongside corporate insiders? There is a way you can do this — and it is perfectly legal. Information about insider share purchases and sales is readily available to anyone who wants to view it. That’s because corporate officers,… Read More

New income investors sometimes make the mistake of looking no further than a stock’s current dividend yield. After all, a stock such as biotech firm PDL BioPharma (NASDAQ: PDL) looks mighty enticing, based on its 10% yield. But looks can be misleading. A closer look at PDL reveals a dividend that may be in trouble. The company’s net income fell by more than 50% last year, and PDL paid out more in dividends than it earned as income. The company earned $92 million, but paid $130 million in… Read More

New income investors sometimes make the mistake of looking no further than a stock’s current dividend yield. After all, a stock such as biotech firm PDL BioPharma (NASDAQ: PDL) looks mighty enticing, based on its 10% yield. But looks can be misleading. A closer look at PDL reveals a dividend that may be in trouble. The company’s net income fell by more than 50% last year, and PDL paid out more in dividends than it earned as income. The company earned $92 million, but paid $130 million in dividends. When earnings decline sharply, even blue-chip companies can sometimes find their dividends in danger. A good example is General Electric (NYSE: GE), which was forced to trim its dividend by two-thirds during the economic downturn. Quarterly payments dropped from $0.31 to just $0.10. [See: “Forget GE, Buy These Stocks Instead”] Another high-profile casualty of the downturn was oil refiner Valero Energy (NYSE: VLO). Valero cut its quarterly dividend from $0.15 to $0.05, which is where the dividend remains today. So how do you protect yourself… Read More

Stock prices have rallied more than 20% in the past 12 months, but it is still possible for investors to find bargains — if they are willing to do a little research. Investing in underpriced stocks often requires patience, since the expectation is generally for a gradual rise in value. But sometimes these stocks attract the attention of corporate raiders and shoot up overnight. This recently happened with Clorox Corp. (NYSE:CLX). An investor group led by Carl Icahn determined Clorox was undervalued and purchased 9% of the outstanding stock, which resulted in surge of about 9% in… Read More

Stock prices have rallied more than 20% in the past 12 months, but it is still possible for investors to find bargains — if they are willing to do a little research. Investing in underpriced stocks often requires patience, since the expectation is generally for a gradual rise in value. But sometimes these stocks attract the attention of corporate raiders and shoot up overnight. This recently happened with Clorox Corp. (NYSE:CLX). An investor group led by Carl Icahn determined Clorox was undervalued and purchased 9% of the outstanding stock, which resulted in surge of about 9% in Clorox’s share price within two trading days. Before Icahn’s investment, Clorox shares had been trading for 16 times trailing earnings and yielded more than 3%. [To find out what else Icahn has been buying, go here.] #-ad_banner-# I set out to find undervalued wallflowers that missed the market rally by running a screen for mid-cap and large cap stocks that trade at price-to-earnings (P/E) multiples well below the S&P 500. My screen looked at both trailing 12-month P/E and forward P/E multiples. Read More